logo
Menu
Innovation Observatory > Reports > Drugs > Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

< Back

Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Drugs

Cardiovascular Disease and Vascular Surgery

November 2017


Rivaroxaban and aspirin are drugs that reduce blood clots in blood vessels and are currently being given to some patients with CAD and PAD. The combination of rivaroxaban with aspirin is being developed as a more effective treatment. If licensed, this combination will offer a new option for the prevention of major cardiovascular events.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Rivaroxaban for Prevention of Cardiovascular Events



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts
Get Alerts